



CHOLESTATIC PRURITUS ASSOCIATED WITH PBC: UNDERSTANDING UNMET PATIENT NEEDS AND TREATMENT STRATEGIES

References:

- Bedoyan SM, Lovell OT, Horslen SP, Squires JE. Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis. *Expert Opin Pharmacother*. 2022;23(16):1771-1779. doi:10.1080/14656566.2022.2140040
- Corpechot C, Chazouillères O, Rousseau A, et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. *N Engl J Med*. 2018;378(23):2171-2181. doi:10.1056/NEJMoa1714519
- Decock S, Roelandts R, Steenberghe WW, et al. Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study. *J Hepatol*. 2012;57(3):637-641. doi:10.1016/j.jhep.2012.04.023
- Düll MM, Kremer AE. Evaluation and management of pruritus in primary biliary cholangitis. *Clin Liver Dis*. 2022;26(4):727-745. doi:10.1016/j.cld.2022.06.009
- Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: a new measure of pruritus. *Br J Dermatol*. 2010;162(3):587-593. doi:10.1111/j.1365-2133.2009.09586.x
- GlaxoSmithKline. Lincosib shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC). Published November 19, 2024. Accessed December 13, 2024. <https://www.gsk.com/en-gb/media/press-releases/lincosib-shows-positive-phase-iii-results-in-cholestatic-pruritus/>
- Hegade VS, Bolier R, Oude Elferink RP, Beuers U, Kendrick S, Jones DE. A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis. *Frontline Gastroenterol*. 2016;7(3):158-166. doi:10.1136/flgastro-2015-100618
- Hegade VS, Krawczyk M, Kremer AE, et al. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. *Aliment Pharmacol Ther*. 2016;43(2):294-302. doi:10.1111/apt.13449
- Hegade VS, Mells GF, Fisher H, et al. Pruritus is common and undertreated in patients with primary biliary cholangitis in the United Kingdom. *Clin Gastroenterol Hepatol*. 2019;17(7):1379-1387.e3. doi:10.1016/j.cgh.2018.12.007
- Hirschfield GM, Bowlus CL, Mayo MJ, et al. A phase 3 trial of seladelpar in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):783-794. doi:10.1056/NEJMoa2312100
- Iqirvo. Prescribing information. Ipsen Biopharmaceuticals, Inc. Accessed December 13, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218860s000lbl.pdf
- Jacoby A, Rannard A, Buck D, et al. Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis. *Gut*. 2005;54(11):1622-1629. doi:10.1136/gut.2005.065862
- Jeyaraj R, Maher ER, Kelly D. Paediatric research sets new standards for therapy in paediatric and adult cholestasis. *Lancet Child Adolesc Health*. 2024;8(1):75-84. doi:10.1016/S2352-4642(23)00259-6
- Kowdley KV, Bowlus CL, Levy C, et al. Efficacy and safety of elafibranor in primary biliary cholangitis. *N Engl J Med*. 2024;390(9):795-805. doi:10.1056/NEJMoa2306185
- Krawczyk M, Liebe R, Wasilewicz M, Wunsch E, Raszeja-Wyszomirska J, Milkiewicz P. Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch. *Liver Int*. 2017;37(5):743-747. doi:10.1111/liv.13281
- Lammers WJ, van Buuren HR, Hirschfield GM, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. *Gastroenterology*. 2014;147(6):1338-e15. doi:10.1053/j.gastro.2014.08.029
- Levy C, Kendrick S, Bowlus CL, et al. GLIMMER: a randomized phase 2b dose-ranging trial of lincosib in primary biliary cholangitis patients with pruritus. *Clin Gastroenterol Hepatol*. 2023;21(7):1902-1912.e13. doi:10.1016/j.cgh.2022.10.032
- Levy C, Manns M, Hirschfield G. New treatment paradigms in primary biliary cholangitis. *Clin Gastroenterol Hepatol*. 2023;21(8):2076-2087. doi:10.1016/j.cgh.2023.02.005



CHOLESTATIC PRURITUS ASSOCIATED WITH PBC: UNDERSTANDING UNMET PATIENT NEEDS AND TREATMENT STRATEGIES

Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2019;69(1):394-419. doi:10.1002/hep.30145

Livdelzi. Prescribing information. Gilead Sciences, Inc. Accessed December 13, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217899s000lbl.pdf

Leo A, Jepsen P, Morengi E, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. *Sci Rep*. 2016;6:25906. doi:10.1038/srep25906

Mayo MJ, Carey E, Smith HT, et al. Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis [published correction appears in *Dig Dis Sci*. 2023 Oct;68(10):4064-4065. doi:10.1007/s10620-023-08050-9]. *Dig Dis Sci*. 2023;68(3):995-1005. doi:10.1007/s10620-022-07581-x

Mirum Pharmaceuticals Inc. Mirum's volixibat achieves positive interim analyses in VANTAGE PBC and VISTAS PSC studies. Mirumpharma.com. Published June 17, 2024. Accessed December 13, 2024. https://ir.mirumpharma.com/news-events/News/news-details/2024/Mirums-Volixibat-Achieves-Positive-Interim-Analyses-in-VANTAGE-PBC-and-VISTAS-PSC-Studies/default.aspx#xd_co_f=NzlmOThkOGYtZGVIMy00Nzk4LTlkNTItZDY1Zjk4YmM1YjVh~

Parés A, Herrera M, Avilés J, Sanz M, Mas A. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. *J Hepatol*. 2010;53(2):307-312. doi:10.1016/j.jhep.2010.02.031

Rishe E, Azarm A, Bergasa NV. Itch in primary biliary cirrhosis: a patients' perspective. *Acta Derm Venereol*. 2008;88(1):34-37. doi:10.2340/00015555-0350

Talwalkar JA, Souto E, Jorgensen RA, Lindor KD. Natural history of pruritus in primary biliary cirrhosis. *Clin Gastroenterol Hepatol*. 2003;1(4):297-302.

Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of pruritus in primary biliary cholangitis: a narrative review. *Am J Med*. 2017;130(6):744.e1-744.e7. doi:10.1016/j.amjmed.2017.01.037